Orexo is a Swedish pharmaceutical company with a focus on the therapeutic areas of pain and inflammation. Orexo’s first proprietary developed drug, Abstral, for the treatment of breakthrough pain in cancer patients was launched in Europe in 2008. The second drug, Edluar - for the short-term treatment of insomnia was launched in the USA in 2009. Orexo has a number of projects in the pipeline and also markets two diagnostic products for the gastric ulcer bacteria, Helicobacter pylori, through its Kibion subsidiary.